171 related articles for article (PubMed ID: 36961847)
1. Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study.
Aomar-Millán IF; de Victoria-Carazo JM; Fernández Reyes D; Torres-Parejo Ú; Pérez Fernández L; Martínez-Diz S; Ceballos Torres A; López Gómez J; Bizzarri F; Raya Álvarez E; Salvatierra J
PLoS One; 2023; 18(3):e0283529. PubMed ID: 36961847
[TBL] [Abstract][Full Text] [Related]
2. Association of COVID-19 Vaccinations With Intensive Care Unit Admissions and Outcome of Critically Ill Patients With COVID-19 Pneumonia in Lombardy, Italy.
Grasselli G; Zanella A; Carlesso E; Florio G; Canakoglu A; Bellani G; Bottino N; Cabrini L; Castelli GP; Catena E; Cecconi M; Cereda D; Chiumello D; Forastieri A; Foti G; Gemma M; Giudici R; Grazioli L; Lombardo A; Lorini FL; Madotto F; Mantovani A; Mistraletti G; Mojoli F; Mongodi S; Monti G; Muttini S; Piva S; Protti A; Rasulo F; Scandroglio AM; Severgnini P; Storti E; Fumagalli R; Pesenti A;
JAMA Netw Open; 2022 Oct; 5(10):e2238871. PubMed ID: 36301541
[TBL] [Abstract][Full Text] [Related]
3. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
[TBL] [Abstract][Full Text] [Related]
4. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.
CORIMUNO-19 Collaborative group
Lancet Respir Med; 2021 Mar; 9(3):295-304. PubMed ID: 33493450
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
6. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
[TBL] [Abstract][Full Text] [Related]
7. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.
Aomar-Millán IF; Salvatierra J; Torres-Parejo Ú; Faro-Miguez N; Callejas-Rubio JL; Ceballos-Torres Á; Cruces-Moreno MT; Gómez-Jiménez FJ; Hernández-Quero J; Anguita-Santos F
Intern Emerg Med; 2021 Jun; 16(4):843-852. PubMed ID: 33400157
[TBL] [Abstract][Full Text] [Related]
8. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
[TBL] [Abstract][Full Text] [Related]
9. Anakinra or high-dose corticosteroids in COVID-19 pneumonia patients who deteriorate on low-dose dexamethasone: an observational study of comparative effectiveness.
Langer-Gould A; Xu S; Myers LC; Chen A; Greene JD; Creekmur B; Bruxvoort K; Adams JL; Liu V; Gould MK
Int J Infect Dis; 2023 Jan; 126():87-93. PubMed ID: 36403818
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial.
Fanlo P; Gracia-Tello BDC; Fonseca Aizpuru E; Álvarez-Troncoso J; Gonzalez A; Prieto-González S; Freire M; Argibay AB; Pallarés L; Todolí JA; Pérez M; Buján-Rivas S; Ibáñez B;
JAMA Netw Open; 2023 Apr; 6(4):e237243. PubMed ID: 37027155
[TBL] [Abstract][Full Text] [Related]
11. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
12. Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study.
Segala FV; Rando E; Salvati F; Negri M; Catania F; Sanmartin F; Murri R; Giamarellos-Bourboulis EJ; Fantoni M
PLoS One; 2023; 18(4):e0273202. PubMed ID: 37014833
[TBL] [Abstract][Full Text] [Related]
13. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study.
Kooistra EJ; Waalders NJB; Grondman I; Janssen NAF; de Nooijer AH; Netea MG; van de Veerdonk FL; Ewalds E; van der Hoeven JG; Kox M; Pickkers P;
Crit Care; 2020 Dec; 24(1):688. PubMed ID: 33302991
[TBL] [Abstract][Full Text] [Related]
14. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region.
Majmundar M; Kansara T; Lenik JM; Park H; Ghosh K; Doshi R; Shah P; Kumar A; Amin H; Chaudhari S; Habtes I
PLoS One; 2020; 15(9):e0238827. PubMed ID: 32903258
[TBL] [Abstract][Full Text] [Related]
16. Patients diagnosed with COVID-19 and treated with anakinra: a real-world study in the USA.
Rich C; Eriksson D; Dolfi F; Jablonska K; Dabbous F; Nazir J
Clin Exp Immunol; 2022 Apr; 207(2):218-226. PubMed ID: 35020840
[TBL] [Abstract][Full Text] [Related]
17. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply.
Aomar-Millán IF; Salvatierra J; Hernández-Quero J
Intern Emerg Med; 2021 Jun; 16(4):1105-1106. PubMed ID: 33694056
[No Abstract] [Full Text] [Related]
18. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment.
Yurttutan S; Gullu UU; Ipek S
Intern Emerg Med; 2021 Jun; 16(4):1101-1103. PubMed ID: 33598871
[No Abstract] [Full Text] [Related]
19. Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm.
Jackson LE; Khullar N; Beukelman T; Chapleau C; Kamath A; Cron RQ; Chatham WW
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896812
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab versus anakinra in COVID-19: results from propensity score matching.
Arcani R; Correard F; Suchon P; Kaplanski G; Jean R; Cauchois R; Leprince M; Arcani V; Seguier J; De Sainte Marie B; Andre B; Koubi M; Rossi P; Gayet S; Gobin N; Garrido V; Weiland J; Jouve E; Couderc AL; Villani P; Daumas A
Front Immunol; 2023; 14():1185716. PubMed ID: 37304271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
